NICE backs kidney cancer combination from Merck KGaA and PfizerNICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first Share XNICE backs kidney cancer combination from Merck KGaA and Pfizerhttps://pharmaphorum.com/news/nice-backs-kidney-cancer-combination-from-merck-kgaa-and-pfizer/
Merck KGaA takes second option from cancer immunotherapy pact with F-StarGermany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics. The companies Share XMerck KGaA takes second option from cancer immunotherapy pact with F-Starhttps://pharmaphorum.com/news/merck-kgaa-takes-second-option-from-cancer-immunotherapy-pact-with-f-star/
Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial successMerck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in Share XMerck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial successhttps://pharmaphorum.com/news/mercks-atr-cancer-drug-cleared-for-clinical-trials-after-phase-1-trial-success/
Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerMerck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, Share XMerck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/
FDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerThe FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated Share XFDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerhttps://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaa-combo-in-advanced-colorectal-cancer/
BI opens second branch of digital lab in ChinaBoehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in Share XBI opens second branch of digital lab in Chinahttps://pharmaphorum.com/news/bi-opens-branch-of-digital-lab-in-china/
The many faces of patient-pharma co-creationAhead of her appearance at eyeforpharma Barcelona, Merck’s director of patient advocacy and strategic partnerships, Vanessa Pott, tells Share XThe many faces of patient-pharma co-creationhttps://pharmaphorum.com/views-analysis-patients/the-many-faces-of-patient-pharma-co-creation-merck-eyeforpharma/
Merck, Pfizer’s Bavencio flunks head and neck cancer trialMerck KGaA and Pfizer’s checkpoint inhibitor Bavencio has failed a phase 3 trial in head and neck cancer, Share XMerck, Pfizer’s Bavencio flunks head and neck cancer trialhttps://pharmaphorum.com/news/merck-pfizers-bavencio-flunks-head-and-neck-cancer-trial/
Merck partners with tech firm AMCM on tablet 3D printingMerck KGaA has partnered with German tech company AMCM to carry out clinical testing on tablets manufactured using Share XMerck partners with tech firm AMCM on tablet 3D printinghttps://pharmaphorum.com/news/merck-partners-with-tech-firm-amcm-on-tablet-3d-printing/
